Dihexa Protocol: Complete Cycling & Dosing Guide

Overview

Dihexa is a synthetic peptide derived from angiotensin IV, developed as a potent cognitive enhancer with demonstrated synaptogenic and neuroprotective properties in preclinical research. It functions as a hepatocyte growth factor (HGF) agonist, activating the MET receptor tyrosine kinase pathway and the AT4 receptor to promote synaptic connectivity, dendritic spine growth, and neuroplasticity.

Critical Context: Dihexa has never completed human clinical trials. All dosing and safety information presented here is derived from anecdotal reports and rodent studies. The true risk profile in humans remains unknown. Long-term or high-dose use cannot be considered safe by current evidence standards.

Key characteristics:

• Type: Small peptide (peptidomimetic)
• Primary mechanism: HGF/c-Met and AT4 receptor agonism
• Potency: Reportedly ~10 million times more potent than BDNF for synaptogenesis in animal models
• Bioavailability: Orally bioavailable (unusual for peptides)
• Research focus: Cognitive enhancement, neuroprotection, neurodegenerative disease reversal

Standard Protocol

Dosing by Route

Oral Administration:

• Dose range: 10–30 mg once daily
• Standard starting dose: 10 mg/day
• Maximum recommended: 30 mg/day

Sublingual Administration:

• Dose range: 5–15 mg once daily
• Standard starting dose: 5 mg/day
• Maximum recommended: 15 mg/day

Transdermal Application:

• Limited anecdotal data available
• Doses not standardized in available reports
• Patch dosing typically 10–20 mg for 24-hour delivery

Cycle Structure

Standard 8-Week Cognitive Enhancement Cycle:

• Weeks 1–2: Loading phase (10 mg/day oral or 5 mg/day sublingual)
• Weeks 3–6: Maintenance phase (20 mg/day oral or 10 mg/day sublingual)
• Weeks 7–8: High-response phase (25–30 mg/day oral or 12–15 mg/day sublingual)
• Break: 2–4 weeks off before resuming

Conservative Beginner Cycle:

• Weeks 1–4: 10 mg/day oral
• Weeks 5–8: 15 mg/day oral
• Break: 4 weeks off

Timing Considerations

Critical: Take dihexa in the early morning or early afternoon only. Evening or nighttime dosing frequently causes insomnia and sleep disturbances.

• Optimal window: 6:00–11:00 AM
• Acceptable window: 11:00 AM–2:00 PM
• Avoid: After 2:00 PM

With food: Oral dihexa can be taken with or without food; food does not significantly impact bioavailability based on available anecdotal reports.

Goal-Specific Protocols

Protocol A: Cognitive Enhancement & Memory

Duration: 8–10 weeks Dose: 15–25 mg/day oral Timing: 8:00 AM daily

Expected outcomes: Improved working memory, faster recall, enhanced learning consolidation (if effects occur).

Protocol B: Neuroprotection & Neuroplasticity

Duration: 12 weeks (longer cycle for neuroprotective adaptation) Dose: 10–20 mg/day oral Timing: 8:00 AM daily

Stack compatibility: Pairs well with BDNF enhancers (NSI-189, semax) due to complementary pathways.

Protocol C: Conservative/Cautious Approach

Duration: 4 weeks Dose: 10 mg/day oral Timing: 9:00 AM daily

Rationale: Given the unknown long-term safety profile and irreversible effects on synaptic architecture, conservative dosing is justified for first-time users or those with pre-existing hypertension or anxiety disorders.

How to Administer Step-by-Step

Oral Administration

1. Measure: Use a calibrated mg scale or pre-measured capsules (preferred). Do not estimate by eye.
2. Timing: Administer between 7:00–11:00 AM on an empty stomach or with breakfast.
3. Consumption: Swallow with 8 oz of water. Some users report slightly bitter taste if powder touches tongue directly.
4. Consistency: Take at the same time each morning to establish predictable kinetics.
5. Documentation: Log date, dose, time, and any subjective effects (mood, focus, sleep quality, anxiety level, blood pressure if monitored).

Sublingual Administration

1. Measure: Accurately weigh 5–10 mg on a calibrated scale.
2. Placement: Place powder under the tongue and allow it to dissolve without swallowing immediately.
3. Duration: Keep sublingual for 2–3 minutes to allow mucosal absorption.
4. Timing: Early morning (7:00–10:00 AM) recommended.
5. Hydration: Drink water after absorption to clear residue.

Advantage: Sublingual administration may bypass first-pass hepatic metabolism, potentially increasing bioavailability and requiring lower doses.

Transdermal Administration (Patch)

1. Preparation: Transdermal patches are not commonly available commercially; most users prepare custom patches using DMSO, ethanol, or proprietary patch matrices.
2. Application site: Apply to clean, dry, hairless skin (inner wrist, behind ear, or inner thigh).
3. Occlusion: Cover patch with occlusive tape to enhance penetration.
4. Timing: Apply early morning; rotate application sites daily to avoid skin irritation.
5. Removal: Remove after 24 hours; wait 48 hours before reapplying to the same site.

Cycle Example: Week-by-Week Schedule

Protocol: 8-Week Standard Cognitive Enhancement

What to Expect: Timeline of Effects

Days 1–7 (First Week)

• Mood: Potential increase in mental alertness, or conversely, anxiety/restlessness in sensitive individuals.
• Sleep: Sleep quality usually normal if dose taken before 2:00 PM.
• Cognition: Unlikely to notice dramatic changes; too early for adaptive effects.
• Cardiovascular: Possibly subtle elevation in resting heart rate or blood pressure.

Days 8–14 (Second Week)

• Mood: Baseline mood effects become clearer; some users report elevated motivation.
• Anxiety: Anxiety or mental restlessness may emerge; more common at higher doses or in predisposed individuals.
• Focus: Mild improvements in sustained attention reported anecdotally.
• Sleep: If sleep problems develop, verify dosing time is before 2:00 PM; if so, consider dose reduction.

Weeks 3–4 (First Maintenance Phase)

• Cognition: If effects occur, working memory and processing speed improvements become noticeable.
• Mood: Emotional response stabilizes; initial anxiety/restlessness typically resolves or becomes manageable.
• Sleep: Should normalize; insomnia is typically dose-time dependent.
• Physical: No dramatic physical changes expected (dihexa is not studied for muscle/athletic outcomes).

Weeks 5–8 (Extended Cycle)

• Memory: Improved information retention and recall speed reported by some users.
• Focus: Enhanced ability to sustain attention on complex tasks.
• Motivation: Increased mental engagement and curiosity (anecdotal).
• Anxiety/Irritability: Possible irritability at higher doses; dose reduction may help.
• Tolerance: Continued improvements are possible; some users report plateau effects after 4–6 weeks.

Post-Cycle (Weeks 9–12)

• Cognitive carryover: Beneficial effects often persist for 2–4 weeks after discontinuation.
• Return to baseline: Gradual return to pre-cycle cognitive baseline by week 8–12 of break.
• Sleep normalization: Sleep quality typically returns to baseline quickly after cycle ends.

Common Protocol Mistakes

Mistake 1: Evening or Nighttime Dosing

Problem: Insomnia, sleep disruption, and delayed sleep onset. Fix: Always dose before 2:00 PM; 8:00 AM is optimal.

Mistake 2: Escalating Too Quickly

Problem: Increased anxiety, irritability, and emotional dysregulation without corresponding cognitive benefits. Fix: Use the structured dose escalation timeline (Weeks 1–2 at 10 mg, Weeks 3–4 at 15 mg, etc.). Do not exceed 30 mg/day oral or 15 mg/day sublingual.

Mistake 3: Exceeding 8-10 Week Cycles

Problem: Diminishing returns, potential tolerance development, and unknown long-term effects on synaptic remodeling. Fix: Strictly adhere to 8-week maximum for standard cycles; longer cycles only under medical supervision. Always take a 3–4 week break minimum.

Mistake 4: Inadequate Break Periods

Problem: Receptor downregulation, tolerance, and compounding effects on blood pressure and anxiety. Fix: Enforce minimum 3–4 week breaks between cycles. This allows MET receptor sensitivity and AT4 receptor function to normalize.

Mistake 5: Ignoring Cardiovascular and Mood Side Effects

Problem: Hypertension, anxiety, and irritability can escalate if unmonitored. Fix: Monitor blood pressure weekly, especially during Weeks 3–8. Log mood, anxiety, and emotional baseline. If significant anxiety or hypertension emerges, reduce dose by 5 mg or discontinue and take a 2-week break.

Mistake 6: Using Inconsistent Timing

Problem: Variable absorption, inconsistent effects, and difficulty distinguishing actual effects from placebo. Fix: Dose at the same time every morning (ideally 8:00 AM).

Mistake 7: Stacking Multiple Neurotropic Peptides Without Spacing

Problem: Excessive synaptogenic activity, anxiety, sleep disruption. Fix: If stacking, stagger administration or reduce dihexa dose by 25–30%. See stacking section below.

How to Stack with Other Compounds

Dihexa's mechanism (HGF/c-Met and AT4 agonism) provides complementary stacking opportunities with other neurotropic agents. However, caution is warranted given the unknown safety profile.

Stack 1: Dihexa + NSI-189 (Neurogenesis & Neuroprotection)

Rationale: Both promote synaptic growth through different pathways (dihexa via HGF/c-Met, NSI-189 via p-CREB). Synergistic but potent combination.

Protocol:

• Dihexa: 15 mg/day oral (morning)
• NSI-189: 40 mg/day oral (split: 20 mg morning, 20 mg midday)
• Cycle: 8 weeks on, 4 weeks off
• Note: Monitor mood and anxiety closely; reduce dihexa to 10 mg if anxiety emerges.

Stack 2: Dihexa + Semax (Cognitive Enhancement + Mood Regulation)

Rationale: Semax enhances ACTH, endorphins, and cognitive resilience; dihexa enhances synaptic connectivity. Complementary without receptor overlap.

Protocol:

• Dihexa: 15 mg/day oral (8:00 AM)
• Semax: 1 mg/day intranasal or sublingual (separate from dihexa by 2 hours)
• Cycle: 8 weeks on, 3 weeks off
• Note: Semax can reduce anxiety associated with dihexa; synergistic safety profile.

Stack 3: Dihexa + NeuroGenesis Support (Choline + L-Theanine)

Rationale: Precursor support and anxiolytic stabilization for dihexa's stimulant-like properties.

Protocol:

• Dihexa: 15–20 mg/day oral (8:00 AM)
• Alpha-GPC: 300 mg/day (with dihexa dose)
• L-Theanine: 100–200 mg/day as needed for anxiety (2:00–4:00 PM)
• Cycle: 8 weeks on, 3 weeks off
• Note: L-Theanine can mitigate anxiety without compromising cognitive benefits.

Stack 4: Dihexa + BDNF Boosters (Cerebolysin, NAD+)

Rationale: BDNF enhancement synergizes with dihexa's HGF/c-Met signaling for amplified neuroplasticity.

Protocol:

• Dihexa: 12 mg/day oral (reduce slightly to account for stacking)
• NAD+ Precursor (NMN): 500 mg/day (morning)
• Cycle: 8 weeks on, 4 weeks off
• Caution: Do not combine with cerebolysin (IV peptide) without medical oversight; excessive peptide stacking poses unknown risks.

Avoid These Stacks

• Dihexa + other AT4 agonists: Risk of excessive angiotensin signaling and hypertension.
• Dihexa + stimulants (amphetamine, modafinil, high-dose caffeine): Additive cardiovascular stress and anxiety.
• Dihexa + multiple synaptogenic peptides: Excessive neurological activity; risk uncharacterized.

Protocol Quick Reference